Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Valneva SE

Market Cap 432M 502M 398M 374M 702M 47.42B 709M 4.7B 1.83B 23.22B 1.88B 1.84B 80.47B P/E Ratio 2026 *
-6.21x
P/E Ratio 2027 * 6x
Enterprise Value 560M 650M 516M 484M 909M 61.46B 919M 6.1B 2.37B 30.1B 2.44B 2.39B 104B EV / Sales 2026 *
3.69x
EV / Sales 2027 * 1.67x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day-0.61%
1 week+0.85%
Current month-13.28%
1 month-8.19%
3 months-52.05%
6 months-36.30%
Current year-39.08%
1 week 2.18
Extreme 2.182
2.37
1 month 2.18
Extreme 2.182
2.72
Current year 2.14
Extreme 2.135
5.15
1 year 2.14
Extreme 2.135
5.42
3 years 1.73
Extreme 1.726
7.85
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap.
27/01Sell

Chief Technology Officer

11,800 0.0069%
26/01Sell

Chief Financial Officer

11,800 0.0069%
19/01Sell

Chief Technology Officer

66,139 0.0385%
Change 5-day change 1-year change 3-year change Capi.($)
-0.61%+0.85%-9.33%-66.61% 502M
+0.15%-0.92%-11.68%-9.95% 43.51B
-2.17%+4.70%+293.71%+535.99% 33.29B
-1.60%-1.58%-0.19%+31.82% 29.34B
+0.44%-3.80%+12.51%-17.06% 29.9B
-0.29%+2.65%+13.24%+21.04% 25.42B
+3.54%+8.43% - - 14.36B
-1.26%-1.11%+53.37%+108.10% 13.18B
-0.99%-5.04%+2.44%+3.53% 12.72B
-1.18%-2.00%+107.41%+78.18% 12.08B
Average -0.38%+0.54%+51.28%+76.12% 21.43B
Weighted average by Cap. -0.44%+0.63%+60.02%+103.77%

Financials

2026 *2027 *
Net sales 152M 176M 140M 131M 246M 16.66B 249M 1.65B 644M 8.16B 661M 647M 28.27B 294M 341M 271M 254M 477M 32.26B 482M 3.2B 1.25B 15.8B 1.28B 1.25B 54.74B
Net income -66.01M -76.6M -60.79M -57.07M -107M -7.24B -108M -718M -280M -3.55B -287M -281M -12.29B 70.5M 81.81M 64.92M 60.95M 114M 7.73B 116M 767M 299M 3.79B 307M 300M 13.13B
Net Debt 128M 149M 118M 111M 208M 14.04B 210M 1.39B 543M 6.88B 557M 546M 23.83B 60.02M 69.64M 55.27M 51.89M 97.42M 6.58B 98.45M 653M 254M 3.22B 261M 256M 11.17B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change Volume
17/06/26 2.265 -0.61% 73,283
16/06/26 2.279 -0.57% 412,911
15/06/26 2.292 +0.26% 336,120
12/06/26 2.286 +3.25% 352,774
11/06/26 2.214 -1.42% 583,232
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.279EUR
Average target price
5.233EUR
Spread / Average Target
+129.63%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!